Comparison of vaccine strategies against congenital CMV infection in the guinea pig model

Journal of Clinical Virology

Volumn 41, Issue 3, 2008, Pages 224-230

  Schleiss, Mark R ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

CMV vaccines; Congenital CMV; Guinea pig cytomegalovirus; Guinea pig model

Indexed keywords

CYTOMEGALOVIRUS VACCINE; DNA VACCINE; GLYCOPROTEIN 83; GLYCOPROTEIN B; LIVE VACCINE; RECOMBINANT GLYCOPROTEIN B; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; GUINEA PIG; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ANIMALS; ANIMALS, NEWBORN; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; DISEASE MODELS, ANIMAL; FEMALE; GUINEA PIGS; HUMANS; PHOSPHOPROTEINS; PREGNANCY; PREGNANCY OUTCOME; VACCINES, ATTENUATED; VACCINES, DNA; VIRAL ENVELOPE PROTEINS; VIRAL MATRIX PROTEINS;

EID: 38949131854     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2007.10.008     Document Type: Article

References (40)

1. Arvin A.M., Fast P., Myers M., Plotkin S., Rabinovich R., and National Vaccine Advisory Committee. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis 39 (2004) 233-239
2. Berencsi K., Gyulai Z., Gonczol E., Pincus S., Cox W.I., Michelson S., et al. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J Infect Dis 183 (2001) 1171-1179
3. Bia F.J., Griffith B.P., Tarsio M., and Hsuing G.D. Vaccination for the prevention of maternal and fetal infection with guinea pig cytomegalovirus. J Infect Dis 142 (1980) 732-738
4. Bourne N., Schleiss M.R., Bravo F.J., and Bernstein D.I. Preconception immunization with a cytomegalovirus (CMV) glycoprotein vaccine improves pregnancy outcome in a guinea pig model of congenital CMV infection. J Infect Dis 183 (2001) 59-64
5. Britt W.J., and Boppana S. Human cytomegalovirus virion proteins. Hum Immunol 65 (2004) 395-402
6. Griffith B.P., Lucia H.L., and Hsuing G.D. Brain and visceral involvement during congenital cytomegalovirus infection of guinea pigs. Pediatr Res 16 (1982) 455-459
7. Guma M., Angulo A., and Lopez-Botet M. NK cell receptors involved in the response to human cytomegalovirus infection. Curr Top Microbiol Immunol 298 (2006) 207-223
8. Haggerty S.M., and Schleiss M.R. A novel CC-chemokine homolog encoded by guinea pig cytomegalovirus. Virus Genes 25 (2002) 271-279
9. Harrison C.J., Britt W.J., Chapman N.M., Mullican J., and Tracy S. Reduced congenital cytomegalovirus (CMV) infection after maternal immunization with a guinea pig CMV glycoprotein before gestational primary CMV infection in the guinea pig model. J Infect Dis 172 (1995) 1212-1220
10. Hartley J.W., Rowe W.P., and Huebner R.J. Serial propagation of the guinea pig salivary gland virus in tissue culture. Proc Soc Exp Biol Med 96 (1957) 281-285
11. Heineman T.C., Schleiss M., Bernstein D.I., Spaete R.R., Yan L., Duke G., et al. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis 193 (2006) 1350-1360
12. Kaufmann P., and Davidoff M. The guinea-pig placenta. Adv Anat Embryol Cell Biol 53 (1977) 5-91
13. Kern F., Bunde T., Faulhaber N., Kiecker F., Khatamzas E., Rudawski I.M., et al. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J Infect Dis 185 (2002) 1709-1716
14. Lacey S.F., Gallez-Hawkins G., Crooks M., Martinez J., Senitzer D., Forman S.J., et al. Characterization of cytotoxic function of CMV-pp65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants. Transplantation 74 (2002) 722-732
15. Lazzarotto T., Varani S., Guerra B., Nicolosi A., Lanari M., and Landini M.P. Prenatal indicators of congenital cytomegalovirus infection. J Pediatr 137 (2000) 90-95
16. Leiser R., and Kaufmann P. Placental structure: in a comparative aspect. Exp Clin Endocrinol 102 (1994) 122-134
17. McGregor A., Liu F., and Schleiss M.R. Identification of essential and non-essential genes of the guinea pig cytomegalovirus (GPCMV) genome via transposome mutagenesis of an infectious BAC clone. Virus Res 101 2 (2004) 101-108
18. McLaughlin-Taylor E., Pande H., Forman S.J., Tanamachi B., Li C.R., Zaia J.A., et al. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol 43 (1994) 103-110
19. Noonan D. The guinea pig (Cavia porcellus). Anzccart News 7 (1994) 1-8
20. Penfold M., Miao Z., Wang Y., Haggerty S., and Schleiss M.R. A macrophage inflammatory protein homolog encoded by guinea pig cytomegalovirus signals via CC chemokine receptor 1. Virology 316 (2003) 202-212
21. Reeves M., Cui X., Schleiss M., and McVoy M. Potential role of guinea pig cytomegalovirus (GPCMV) MHC homologs in NK-evasion. Abstracts of 32nd International Herpesvirus Workshop, vol. 9 (2007) p. 13
22. Revello M.G., and Gerna G. Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin Microbiol Rev 15 (2002) 680-715
23. Sasaki S., Takeshita F., Xin K.Q., Ishii N., and Okuda K. Adjuvant formulations and delivery systems for DNA vaccines. Methods 31 (2003) 243-254
24. Schleiss M.R. Cloning and characterization of the guinea pig cytomegalovirus glycoprotein B gene. Virology 202 (1994) 173-185
25. Schleiss M.R., Bourne N., Jensen N.J., Bravo F., and Bernstein D.I. Immunogenicity evaluation of DNA vaccines that target guinea pig cytomegalovirus proteins glycoprotein B and UL83. Viral Immunol 13 (2000) 155-167
26. Schleiss M.R., Bourne N., and Bernstein D.I. Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea pig model of congenital CMV infection. J Infect Dis 188 (2003) 1868-1874
27. Schleiss M.R., and Jensen N.J. Cloning and expression of the guinea pig cytomegalovirus glycoprotein B (gB) in a recombinant baculovirus: utility for vaccine studies for the prevention of experimental infection. J Virol Methods 108 (2003) 59-65
28. Schleiss M.R., Bourne N., Stroup G., Bravo F.J., Jensen N.J., and Bernstein D.I. Protection against congenital cytomegalovirus (CMV) infection and disease in guinea pigs conferred by a purified recombinant glycoprotein B (gB) vaccine. J Infect Dis 189 (2004) 1374-1381
29. Schleiss M.R., and Lacayo J.C. The guinea pig model of congenital CMV infection. In: Reddehase M.J. (Ed). In Cytomegaloviruses: Pathogenesis, Molecular Biology and Infection Control (2005), Horizon Scientific Press Ltd., Wymondham, Norfolk, UK
30. Schleiss M.R., and Heineman T.C. Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev Vac 4 (2005) 381-406
31. Schleiss M.R., Stroup G., Pogorzelski K., and McGregor A. Protection against congenital cytomegalovirus (CMV) disease, conferred by a replication-disabled, bacterial artificial chromosome (BAC)-based DNA vaccine. Vaccine 24 (2006) 6175-6186
32. Schleiss M.R. Nonprimate models of congenital cytomegalovirus (CMV) infection: gaining insight into pathogenesis and prevention of disease in newborns. ILAR J 47 (2006) 65-72
33. Schleiss M.R., and Choo D.I. Mechanisms of congenital cytomegalovirus-induced deafness. Drug Discov Today: Dis Mech 3 (2006) 105-113
34. Schleiss M.R., Lacayo J., Belkaid Y., McGregor A., Stroup G., Rayner J., et al. Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. J Infect Dis 195 (2007) 789-798
35. Selinsky C., Luke C., Wloch M., Geall A., Hermanson G., Kaslow D., et al. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases. Human Vaccines 1 (2005) 16-23
36. Stratton KR, Durch JS, Lawrence RS (Eds). Vaccines for the 21st Century: A Tool for Decisionmaking, Committee to Study Priorities for Vaccine Development, Division of Health Promotion and Disease Prevention, Institute of Medicine, Washington, DC 1999.
37. Wills M.R., Carmichael A.J., Mynard K., Jin X., Weekes M.P., Plachter B., et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 70 (1996) 7569-7579
38. Wills M.R., Ashiru O., Reeves M.B., Okecha G., Trowsdale J., Tomasec P., et al. Human cytomegalovirus encodes an MHC class I-like molecule (UL142) that functions to inhibit NK cell lysis. J Immunol 175 (2005) 7457-7465
39. Woolf N.K., Koehrn F.J., Harris J.P., and Richman D.D. Congenital cytomegalovirus labyrinthitis and sensorineural hearing loss in guinea pigs. J Infect Dis 160 (1989) 929-937
40. Zhang C., and Pass R.F. Detection of cytomegalovirus infection during clinical trials of glycoprotein B vaccine. Vaccine 23 (2004) 507-510